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Predictive medicine, utilizing the ProteinChip Array technology, will develop through the implementation of novel biomarkers
and multimarker patterns for detecting disease, determining patient prognosis, monitoring drug eﬀects such as eﬃcacy or toxicity,
and for deﬁning treatment options. Thesebiomarkers may also serve as novel protein drugcandidates or protein drug targets. In ad-
dition, the technology can be used for discovering small molecule drugs or for deﬁning their mode of action utilizing protein-based
assays. In this review, we describe the following applications of the ProteinChip Array technology: (1) discovery and identiﬁca-
tion of novel inhibitors of HIV-1 replication, (2) serum and tissue proteome analysis for the discovery and development of novel
multimarker clinical assays for prostate, breast, ovarian, and other cancers, and (3) biomarker and drug discovery applications for
neurological disorders.
INTRODUCTION
The ProteinChip Array technology is used for the
discovery, validation, identiﬁcation, and characterization
of disease-associated proteins from biological samples.
The versatile nature of this technology is enabling for a
wide variety of applications in both research and clinical
proteomics and will be reviewed in three application
areas. A recent publication presents the use of the ﬂex-
ibility and power of the ProteinChip Array platform to
elucidate the nature of novel protein inhibitors of HIV-1
replication, the molecules previously known as the CD8+
antiviral factors. Numerous cancer-related publications
have demonstrated the discovery and development of
biomarkers and multimarker patterns for protein-based
predictive medicine. Finally, we discuss a variety of drug
discovery applications using Alzheimer’s disease as the
model system.
SELDI PROTEINCHIP ARRAY TECHNOLOGY
TheProteinChipArraytechnologyisbasedon surface-
enhanced laser desorption/ionization time-of-ﬂight mass
spectrometry(SELDI-TOF-MS)[1].Thekeycomponents
of this technology are the ProteinChip Arrays, the Pro-
teinChipReader,andtheassociatedsoftware.ProteinChip
Arrays use various chromatography surfaces or biologi-
cal surfaces to capture proteins from complex biological
mixtures according to their physicochemical properties.
Chromatographic surfaces are composed of hydrophobic,
hydrophilic, ion exchange, immobilized metal, or other
chemistries. These surfaces are often used for proﬁling
proteins from biological mixtures, for biomarker discov-
ery, and for assay implementation. This is considered a de
novo protein discovery approach in that no prior knowl-
edge of the speciﬁc proteins is required as would be the
case using antibody-based arrays. The activated surfaces
are used to covalently immobilize speciﬁc bait molecules
such as antibodies, receptors, or oligonucleotides often
used for biomolecular interaction studies such as protein-
protein and protein-DNA interactions.
Biological samples such as cell lysates, tissue extracts,
or biological ﬂuids are added to a spot on a ProteinChip
Array and proteins are allowed to bind to the surface
based on the general chromatographic or speciﬁcally de-
signed biological aﬃnity properties. The unbound pro-
teins and mass spectrometric interfering compounds are
washed away and the proteins that are retained on the ar-
ray surface are analyzed and detected by SELDI-TOF-MS
using a ProteinChip Reader (Figure 1). The MS proﬁles
from the various sets of samples are then compared in
a technique described as diﬀerential protein expression
mapping, whereby relative expression levels of proteins
at speciﬁc molecular weights are compared by a variety
of statistical techniques and bioinformatic software sys-
tems [2].
DISCOVERY AND IDENTIFICATION OF HIV
REPLICATION INHIBITORS
HIV has so far infected 40 million people and 20 mil-
lions have died of the AIDS disease. It is expected that238 G. Reddy and E. A. Dalmasso 2003:4 (2003)
The ProteinChip Reader detects as little as 1 femtomole of captured protein
and assigns an accurate molecular weight using time-of-ﬂight mass
spectrometry. Software generates results in various formats, including
a gel view and a protein map that compares protein expression proﬁles.
Wash buﬀers rinse away contaminants
and eliminate background noise.
The surface chemistry of the chip selectively isolates
and captures target proteins from the crude sample.
Binding buﬀers ensure optimal protein binding and
enhance binding selectivity.
Select one of several ProteinChip
Arrays, depending upon application,
and apply only 0.5 µL–500 µL
of biological ﬂuid or tissue extract
to each of the eight spots.
Figure 1. Protein proﬁling protocol. Procedure for preparing the ProteinChip Arrays with biological samples and for analyzing the
retained proteins by SELDI-TOF-MS using a ProteinChip Reader.
around 3 millions more deaths will occur over the next
12 months, equating to over 9,000 deaths per day. Every
day, 15,000 more people are infected. Certain individuals
infected with HIV-1 virus remain in clinically stable con-
dition for many years after the infection and are classiﬁed
as long-term nonprogressors (LTNP). It has been known
for some time that CD8+ T lymphocytes from these in-
d i v i d u a l ss e c r e t eas o l u b l ef a c t o r ,C D 8 + antiviral factor
(CAF), that suppresses HIV-1 replication, irrespective of
viral phenotype [3]. CAF is found in greater abundance
in supernatants from LTNP CD8+ cells and not usually
detected from patients that progress to develop AIDS.
Despite enormous eﬀorts by numerous laboratories
over the past 16 years, the identity of CAF has remained
elusive. Traditional approaches, including protein expres-
sion based on mRNA levels and several proteomic tech-
nologies, had failed to deﬁne the molecules responsible
for the full extent of this activity. Several studies have
shown that CAF lacks full identity to known chemokines.
Interleukin 16 (IL-16) was suggested as the identity of
CAF by Kruth and colleagues [4]; however, it is not
present in all CAF-containing ﬂuids and it only reduces
HIV replication in an acute infection assay at high con-
centrations. Hence, it does not account for the CAF ac-
tivity. It was postulated by Gallo and colleagues that beta-
chemokines such as RANTES, MIP-1-alpha, and MIP-1-
beta were responsible for the antiviral activity of CD8+
cells [5]. But later it was shown that beta-chemokines can
competitively block the R5 viruses that use CCR5 as a
coreceptor but not the X4 viruses that use CXCR4 as a
coreceptor. Since CAF can inhibit both types of viruses,
beta-chemokines do not fully account for CAF activity.
Drs David Ho and Linqi Zhang and their col-
leagues from the Aaron Diamond AIDS Research Center
were supported by the Ciphergen Biomarker Discovery
Center team in their discovery of the identity of CAF.2003:4 (2003) SELDI for Predictive Medicine and Drug Discovery 239
Using Ciphergen’s ProteinChip System in their labora-
tory, Ho and colleagues discovered a cluster of low molec-
ular weight proteins (3.3 to 3.5 kd) that were present
in stimulated CD8+ cells from normal individuals and
LTNP, but not from patients progressing to AIDS. These
unique proteins were enriched by ion exchange followed
by reverse-phase chromatography. “This enrichment and
puriﬁcation process was monitored by SELDI-TOF-MS.”
Following enrichment, these proteins were then deﬁni-
tivelyidentiﬁedashumanalpha-defensin-1,-2,and-3us-
ing Ciphergen’s PCI-1000 ProteinChip Interface on a tan-
dem MS system [6].
These ﬁndings were conﬁrmed by in vitro inhibi-
tion of viral replication for many HIV-1 isolates. An-
tibodies speciﬁc for human alpha-defensins completely
eliminated the CAF activity, while the speciﬁc antibody-
based depletion of the molecules was demonstrated by
an on-chip SELDI-TOF-MS assay. Furthermore, the au-
thors demonstrated that commercially synthesized alpha-
defensins also inhibit the in vitro replication of HIV-1.
Taken together, all of these results indicated that alpha-
defensin-1, -2, and -3 collectively account for most of
the anti-HIV activity of CAF. Detailed mechanism and in
vivo studies will deﬁne the modes of action and biologi-
cal utility of the alpha-defensins. This discovery will have
a profound impact on the development of novel AIDS
therapeutic and diagnostic approaches. This is a power-
ful example demonstrating that in addition to the de novo
discovery of biomarker and multimarker patterns, SELDI
ProteinChip Array technology can identify novel protein
therapeutic drug candidates and assign novel biological
function to known proteins.
MULTIMARKER CLINICAL ASSAYS FOR CANCER
Cancer is the second leading cause of death in the Un-
tied States, exceeded only by heart disease. In the USA,
one out of every four deaths is from cancer. This year
555,000 Americans are expected to die of cancer, more
than 1500 people a day. Discovery and development of
better diagnostics and therapies are urgently needed to
ﬁght this deadly disease. Most current diagnostic tests de-
tect cancer in advanced stages when treatment is often
diﬃcult and prognosis is poor. Numerous studies have
shown that early detection of cancer increases treatment
options and improves survival rates. Novel biomarkers
can be discovered by comparing the diﬀerences in protein
expression proﬁles between serum or tissue extract sam-
ples from cancer patients and normal individuals. SELDI
ProteinChip Array technology has been used extensively
to proﬁle proteins and discover biomarkers in diﬀerent
types of cancers [7, 8, 9].
The laboratories of Drs George Wright, Jr, Daniel
Chan, Lance Liotta, Emanuel Petricoin, and many others
are currently using the SELDI ProteinChip Array technol-
ogy for serum proteome analysis. These laboratories are
focused on the discovery of markers and biomarker pat-
terns for the early detection of prostate, breast, ovarian,
and other cancers. The main objectives of these studies
are to ﬁnd signature proteomic patterns, or multimarker
clinical assays, in serum that diﬀerentiate normal individ-
uals from cancer patients and have clinical performance
better than current single markers, thereby enabling more
accurate diagnoses by accounting for the heterogeneity of
cancer.In thesestudies, protein proﬁling data is generated
bySELDIProteinChipArraytechnologyfollowedbyanal-
ysis utilizing numerous types of multivariate software al-
gorithms.
Research from these laboratories utilizing hundreds
of serum samples per study has led to the discovery of
multiple biomarkers or biomarker patterns that, when
used in combination, have higher clinical sensitivity and
speciﬁcity relative to the best available single-marker as-
says. For example, Wright and colleagues [7] discovered
that a SELDI multimarker proﬁle combining nine dif-
ferent proteins generates an assay with better sensitivity
(83%) and speciﬁcity (97%) for diagnosis of prostate can-
certhantheprostatespeciﬁcantigen(PSA)test.Chanand
colleagues [8] demonstrated that when three newly dis-
covered biomarkers for breast cancer are used in com-
bination, the SELDI assay has a signiﬁcantly higher sen-
sitivity (93%) and speciﬁcity (91%) relative to CA15.3,
the best available protein marker. For ovarian cancer, Li-
otta and Petricoin et al [9] demonstrated that a SELDI
multimarker proﬁle has sensitivity (100%) and speciﬁcity
(95%), compared to the poor performance of the CA125
test.
While studying serum protein proﬁles is helpful in the
early diagnosis of cancer, the ﬁnal conﬁrmation and stag-
ing of the disease comes from examining the tumor tissue
itself. Since tumor tissue is heterogeneous in nature, new
molecular techniques are needed to study the biomark-
ers that are present. Laser capture microdissection (LCM)
developed by Liotta and colleagues at the National Insti-
tutes of Health has enabled researchers to selectively pro-
cure pure population of cells from a stained tissue section
under direct microscopic visualization. The comprehen-
sive analysis of several cancer samples using SELDI-TOF-
MS to generate tissue-speciﬁc proﬁles of LCM-procured
samples has been reported [10, 11]. Wright and col-
leagues [11] used ProteinChip Array technology to dis-
cover several protein biomarkers, in cells procured by
LCM, that were speciﬁcally distinguished prostate can-
cer cells from surrounding normal prostate cells from the
same patient. Pawaletz et al [10] analyzed protein proﬁles
from patient-matched normal, premalignant, malignant,
and metastatic microdissected cell populations from hu-
man esophageal, prostate, breast, ovary, colon, and hep-
atic tissue sections by SELDI-TOF-MS. They obtained
reproducible and discriminatory protein biomarker pro-
ﬁles that diﬀerentiated normal cells from tumor cells and
discriminated diﬀerent tumor types. Coupling LCM for
speciﬁc cell procurement with SELDI ProteinChip Array
technology has a tremendous potential for the discovery240 G. Reddy and E. A. Dalmasso 2003:4 (2003)
of speciﬁc biomarkers that are associated with each stage
of tumor development.
Both serum and tissue proteome analysis by SELDI
ProteinChip Array technology will have great utility in
protein-based predictive medicine as demonstrated in
these studies. Detailed molecular analysis of tissue has
greatpotentialtoassistwithimproveddeﬁnitionoftumor
aggressivenessandpatientprognosis,andtoassistwithse-
lection of appropriate treatment option. Also, SELDI Pro-
teinChip Array multimarker serum protein patterns ap-
pear to perform signiﬁcantly better in diagnosing diﬀer-
ent types of cancers than currently used single-marker as-
says. If these multimarker SELDI-TOF-MS protein pro-
ﬁles are validated in larger and more clinically diverse
study sets, this approach can have immediate and sub-
stantial beneﬁt for the early detection of many kinds of
cancers. As these studies expand, applications for protein-
based predictive medicine will further develop by estab-
lishing multimarker serum assays that address the more
deﬁned clinical questions described above but with a
more easily acquired biological sample, possibly when the
solid tumor itself cannot be located.
BIOMARKER AND DRUG DISCOVERY APPLICATIONS
IN NEUROLOGICAL DISORDERS
The SELDI ProteinChip technology has been used by
several researchers to discover novel biomarkers and mul-
timarker panels that are relevant to the diagnosis and
patient stratiﬁcation for Alzheimer’s disease, Parkinson’s
disease, multiple sclerosis, schizophrenia, HIV-induced
dementia, and so forth. In this section, we focus on drug
discovery applications of SELDI ProteinChip technology
in Alzheimer’s disease (AD). As the most prevalent form
of neurodegenerative disorders, AD aﬀects about 4 mil-
lion people in the USA, generally people over the age of
65. Clinical features of AD include beta-amyloid deposits
in brain, neuritic plaques, and degeneration of synapses
[12]. In the familial forms of AD, mutation in the amy-
loid precursor protein (APP) or in a presenilin gene (PS1
or PS2) leads to increased amounts of the 40- and 42-
amino acid beta-amyloid peptides that are primary com-
ponents of plaques. The peptides originate from the pro-
teolysis of APP by two proteases known as beta-secretase
and gamma-secretase [13]. The advantage of using Pro-
teinChiptechnologyfortheanalysisisthattheycanbede-
tected directly from a wide range of samples including cell
culture supernatant, CSF, and brain/nerve lysates. More-
over, very low amounts of sample are required.
All of the beta-amyloid peptides share a common
N-terminal sequence, so an antibody that is speciﬁcally
raised against this N-terminal sequence can be immobi-
lized on the ProteinChip Array and used to capture beta-
amyloid peptides from complex samples. The SELDI-
TOF-MS analysis of such a capture can be used to mon-
itor the relative amounts of peptides of various lengths,
including many from beta-amyloid 1–15 to 1–42, some
of which correlate more strongly with the development
of AD than others. This assay has been used successfully
to proﬁle peptide variants secreted into the media of cul-
tured human neuronal cells that express the APP [14].
In addition, this assay was used to establish that BACE-
1 is the beta-secretase that is involved in the generation
of beta-amyloid peptides by neurons [15] and to discover
candidate biomarkers for AD from human CSF (unpub-
lished results, 2002). Secretases are thought to be poten-
tialdrugtargetsandthisassayhasbeenwidelyusedtodis-
covernovelsecretaseinhibitors[16],tostudythefunction
of secretase inhibitors [17], and to monitor the changes
of beta-amyloid in serum and brain mediated by beta-
amyloid vaccination [18]. The drug discovery capabilities
of SELDI ProteinChip technology have been best demon-
strated in the various uses of this on-chip assay for mon-
itoring relative changes in various lengths of the beta-
amyloid peptides.
DISCUSSION
In this review, we have described a number of recent
publications that demonstrate the power of the SELDI
ProteinChip Array technology when utilized directly by
the translational medicine clinical researcher. The tech-
nology enables rapid testing of a clinical hypothesis,
whichgreatlyenhancesandacceleratesdiscoverypotential
and will enable protein-based predictive medicine. In the
ﬁrst example, demonstration of alpha-defensin-1, -2, and
-3asnovelinhibitorsofHIV-1replication,thetechnology
was instrumental in discovering and identifying a set of
small proteins that had eluded researchers for 16 years. In
the second set of examples, we summarized results from
several publications presenting serum and tissue pro-
teome analyses. These studies describe the discovery and
development of multimarker clinical assays for prostate,
breast, ovarian, and other cancers. These assays hold great
promise for the early detection of cancer and for develop-
ment of protein-based predictive medicine. Finally, in the
thirdsetofexamples,wedescribedpublicationsthatshow
the utility of the technology as demonstrated by drug dis-
covery applications for AD. In addition to novel applica-
tions for protein-based predictive medicine, the technol-
ogy is powerful in its ability to discover and character-
ize novel protein drug candidates, protein-protein inter-
actions, and signal transduction pathways in the tumor
cells which would in turn be used to customize therapy
speciﬁc for each individual.
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